How U.K.'s approval of a Covid-19 vaccine will help restore public confidence: EL&N London founder
Alexandra Miller, founder of EL&N London, discusses the impact the COVID pandemic has had on businesses that rely on the in-person experience. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
The U.K.’s groundbreaking decision to grant emergency approval to Pfizer and BioNTech’s coronavirus vaccine will likely lead other countries to quickly follow suit, according to one economist.
Regulators in the rest of Europe and the U.S. have yet to decide on granting emergency use of the vaccine, which was developed by the U.S. pharmaceutical giant and its German partner.
The U.K. government announced Wednesday that it had accepted a recommendation from the country’s independent drug regulator, the Medicines and Healthcare products Regulatory Agency, to approve the vaccine, which was seen to be 95% effective at preventing Covid infections in late-stage clinical trials.
The U.K. is the first to formally approve the Pfizer vaccine, its CEO calling the decision a “historic moment” in the fight against the pandemic.
“The U.K.’s approval will be only one of many, but along with that of the U.S. Food and Drug Administration and the European Medicines Agency, it is likely to set the pace for the rest of the world — and for the other vaccines that are awaiting approval,” said Ana Nicholls, managing editor of the Industry Briefing at The Economist Intelligence Unit.
“For the U.K., it means that the priority groups can now start to get vaccinations immediately: that includes healthcare workers and those in care homes (staff and residents) followed by other vulnerable groups — although given two doses are needed the effects won’t be felt until early next year.”
Pfizer and BioNTech only applied to the European Medicines Agency for the conditional marketing authorization of its vaccine on Tuesday. If the authorization is granted, it could enable its use in Europe this month, although that could prove ambitious given that the EMA said it would only complete its review of the vaccine by Dec. 29.
It also said it would conclude its review of Pfizer’s rival coronavirus vaccine, developed by Moderna and seen to be 94% effective at preventing Covid infection, by Jan. 12.
In the U.S., the FDA said late last month that it had scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee on Dec. 10 to discuss the Pfizer/BioNTech request for the emergency use authorization, so a decision could be announced soon after.
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
Видео How U.K.'s approval of a Covid-19 vaccine will help restore public confidence: EL&N London founder канала CNBC Television
The U.K.’s groundbreaking decision to grant emergency approval to Pfizer and BioNTech’s coronavirus vaccine will likely lead other countries to quickly follow suit, according to one economist.
Regulators in the rest of Europe and the U.S. have yet to decide on granting emergency use of the vaccine, which was developed by the U.S. pharmaceutical giant and its German partner.
The U.K. government announced Wednesday that it had accepted a recommendation from the country’s independent drug regulator, the Medicines and Healthcare products Regulatory Agency, to approve the vaccine, which was seen to be 95% effective at preventing Covid infections in late-stage clinical trials.
The U.K. is the first to formally approve the Pfizer vaccine, its CEO calling the decision a “historic moment” in the fight against the pandemic.
“The U.K.’s approval will be only one of many, but along with that of the U.S. Food and Drug Administration and the European Medicines Agency, it is likely to set the pace for the rest of the world — and for the other vaccines that are awaiting approval,” said Ana Nicholls, managing editor of the Industry Briefing at The Economist Intelligence Unit.
“For the U.K., it means that the priority groups can now start to get vaccinations immediately: that includes healthcare workers and those in care homes (staff and residents) followed by other vulnerable groups — although given two doses are needed the effects won’t be felt until early next year.”
Pfizer and BioNTech only applied to the European Medicines Agency for the conditional marketing authorization of its vaccine on Tuesday. If the authorization is granted, it could enable its use in Europe this month, although that could prove ambitious given that the EMA said it would only complete its review of the vaccine by Dec. 29.
It also said it would conclude its review of Pfizer’s rival coronavirus vaccine, developed by Moderna and seen to be 94% effective at preventing Covid infection, by Jan. 12.
In the U.S., the FDA said late last month that it had scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee on Dec. 10 to discuss the Pfizer/BioNTech request for the emergency use authorization, so a decision could be announced soon after.
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
Видео How U.K.'s approval of a Covid-19 vaccine will help restore public confidence: EL&N London founder канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Mukherjee: The projected energy demand is huge... it's going to double in the next few yearsCalls of the Day: On Holding and TeslaCostco's gas sales is a 'fair amount' of revenue, says Telsey Advisory's Joe FeldmanBreaking down shares of Hilton, Expedia and Match GroupSouthwest stock pops on new guidance and strategy shiftBond Report: 5-year auction well receivedZoom deserves another look from investors despite its weak growth, says MAI Capital's Chris GrisantiStarbucks: Here's why Bernstein upgraded the stockThree-Stock Lunch: S&P Homebuilders Index, Nvidia & JPMorganOptions Action: Bearish bets on Arm Holdings after IPOTrade Tracker: Karen Firestone trims Adobe and buys more AutodeskEarnings trajectory is under-appreciated in the near-term, says HSBC's Max KettnerOpenAI may restructure into a for-profit business as two top executives departTrade Tracker: Bill Baruch trims Tesla, sells SLB and buys more Exxon Mobil and Kinder MorganTrade Tracker: Steve Weiss sells Archer-DanielOpening Bell: January 3, 2024Rooney: The labor market drives the consumer, and the consumer drives the economyEmons: Micron's upgraded outlook boosts the tech sector.KKR pays out employees as much as $325k in sale of GeoStabilization InternationalSeptember consumer confidence falls the most in three yearsMicron set to benefit as memory's role in AI is not fully appreciated, says Wells Fargo's Rakers